Patents by Inventor Timothy McAfoos

Timothy McAfoos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240360121
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: March 6, 2024
    Publication date: October 31, 2024
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 11958849
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 16, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Patent number: 11932643
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 19, 2024
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Jason Cross, Jason Burke, Timothy McAfoos, Zhijun Kang
  • Publication number: 20230416261
    Abstract: Provided are ethanediamine-heterocycle compounds, and salts thereof, that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: September 6, 2023
    Publication date: December 28, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy MCAFOOS, Christopher L. CARROLL, Zhijun KANG
  • Publication number: 20230124815
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: April 20, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 11370786
    Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 28, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Patent number: 11173145
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 16, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Jason Cross, Michelle Han, Michael Soth, Timothy McAfoos, Martin Tremblay
  • Publication number: 20210317122
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: February 3, 2021
    Publication date: October 14, 2021
    Inventors: Philip JONES, Jason CROSS, Jason BURKE, Timothy MCAFOOS, Zhijun KANG
  • Patent number: 11046649
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 29, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Timothy McAfoos, Jason Bryant Cross, Michael J. Soth
  • Publication number: 20210137910
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: December 8, 2020
    Publication date: May 13, 2021
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Timothy MCAFOOS
  • Patent number: 10954243
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: March 23, 2021
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Jason Cross, Jason Burke, Timothy Mcafoos, Zhijun Kang
  • Patent number: 10888554
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: January 12, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Timothy McAfoos
  • Publication number: 20200407353
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 31, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20200171017
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: June 24, 2019
    Publication date: June 4, 2020
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Timothy MCAFOOS
  • Publication number: 20200024236
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 23, 2020
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Timothy MCAFOOS, Jason Bryant CROSS, Michael J. SOTH
  • Publication number: 20190389867
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: May 1, 2019
    Publication date: December 26, 2019
    Inventors: Philip JONES, Jason CROSS, Jason BURKE, Timothy MCAFOOS, Zhijun KANG
  • Publication number: 20190365718
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Jason CROSS, Michele HAN, Michael SOTH, Timothy MCAFOOS, Martin TREMBLAY
  • Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 10363248
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Timothy McAfoos